We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA and Eli Lilly Evaluate Xigris for Bleeding Risk
FDA and Eli Lilly Evaluate Xigris for Bleeding Risk
February 6, 2009
The FDA is evaluating the safety of Eli Lilly’s sepsis treatment Xigris after a published study showed an increased risk of serious bleeding and death in some patients taking the drug.